Fig. 5. Immunolocalization of XCAP-E and UBF in control cells and after actinomycin treatment. XL2 cells were incubated for 6 hours in the medium with 5 µg/ml actinomycin D (E-H) or without the drug (A-D). After fixation, cells were processed for immunofluorescence staining with polyclonal anti-XCAP-E1 antibodies (B,F) and human autoimmune serum to UBF (C,G). Cells were stained with DAPI for DNA visualization (A,E). Triple DAPI/XCAP-E/UBF labeling is shown (D,H). Bar, 5 µm.